The global Pulmonary Drug Delivery Systems market size was US$ 3305 million in 2024 and is forecast to a readjusted size of US$ 4391 million by 2031 with a CAGR of 4.2% during the forecast period 2025-2031.
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
The global Pulmonary Drug Delivery Systems market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
By Type: (Dominant Segment vs High-Margin Innovation)
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
By Application: (Core Demand Driver vs Emerging Opportunity)
COPD
Asthma
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., 3M in Europe)
- Emerging Product Trends: Nebulizers adoption vs. Dry Powder Inhaler (DPI) premiumization
- Demand-Side Dynamics: COPD growth in China vs. Asthma potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
India
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Pulmonary Drug Delivery Systems market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Dry Powder Inhaler (DPI) in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Asthma in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Pulmonary Drug Delivery Systems value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Pulmonary Drug Delivery Systems Product Scope
1.2 Pulmonary Drug Delivery Systems by Type
1.2.1 Global Pulmonary Drug Delivery Systems Sales by Type (2020 & 2024 & 2031)
1.2.2 Nebulizers
1.2.3 Dry Powder Inhaler (DPI)
1.2.4 Metered Dose Inhaler (MDI)
1.3 Pulmonary Drug Delivery Systems by Application
1.3.1 Global Pulmonary Drug Delivery Systems Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 COPD
1.3.3 Asthma
1.3.4 Others
1.4 Global Pulmonary Drug Delivery Systems Market Estimates and Forecasts (2020-2031)
1.4.1 Global Pulmonary Drug Delivery Systems Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Pulmonary Drug Delivery Systems Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Pulmonary Drug Delivery Systems Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Pulmonary Drug Delivery Systems Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Pulmonary Drug Delivery Systems Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Pulmonary Drug Delivery Systems Sales Market Share by Region (2020-2025)
2.2.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Region (2020-2025)
2.3 Global Pulmonary Drug Delivery Systems Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Pulmonary Drug Delivery Systems Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Pulmonary Drug Delivery Systems Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Pulmonary Drug Delivery Systems Market Size and Prospective (2020-2031)
2.4.2 Europe Pulmonary Drug Delivery Systems Market Size and Prospective (2020-2031)
2.4.3 China Pulmonary Drug Delivery Systems Market Size and Prospective (2020-2031)
2.4.4 Japan Pulmonary Drug Delivery Systems Market Size and Prospective (2020-2031)
2.4.5 India Pulmonary Drug Delivery Systems Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Pulmonary Drug Delivery Systems Historic Market Review by Type (2020-2025)
3.1.1 Global Pulmonary Drug Delivery Systems Sales by Type (2020-2025)
3.1.2 Global Pulmonary Drug Delivery Systems Revenue by Type (2020-2025)
3.1.3 Global Pulmonary Drug Delivery Systems Price by Type (2020-2025)
3.2 Global Pulmonary Drug Delivery Systems Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Pulmonary Drug Delivery Systems Sales Forecast by Type (2026-2031)
3.2.2 Global Pulmonary Drug Delivery Systems Revenue Forecast by Type (2026-2031)
3.2.3 Global Pulmonary Drug Delivery Systems Price Forecast by Type (2026-2031)
3.3 Different Types Pulmonary Drug Delivery Systems Representative Players
4 Global Market Size by Application
4.1 Global Pulmonary Drug Delivery Systems Historic Market Review by Application (2020-2025)
4.1.1 Global Pulmonary Drug Delivery Systems Sales by Application (2020-2025)
4.1.2 Global Pulmonary Drug Delivery Systems Revenue by Application (2020-2025)
4.1.3 Global Pulmonary Drug Delivery Systems Price by Application (2020-2025)
4.2 Global Pulmonary Drug Delivery Systems Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Pulmonary Drug Delivery Systems Sales Forecast by Application (2026-2031)
4.2.2 Global Pulmonary Drug Delivery Systems Revenue Forecast by Application (2026-2031)
4.2.3 Global Pulmonary Drug Delivery Systems Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Pulmonary Drug Delivery Systems Application
5 Competition Landscape by Players
5.1 Global Pulmonary Drug Delivery Systems Sales by Players (2020-2025)
5.2 Global Top Pulmonary Drug Delivery Systems Players by Revenue (2020-2025)
5.3 Global Pulmonary Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Drug Delivery Systems as of 2024)
5.4 Global Pulmonary Drug Delivery Systems Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Pulmonary Drug Delivery Systems, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Pulmonary Drug Delivery Systems, Product Type & Application
5.7 Global Key Manufacturers of Pulmonary Drug Delivery Systems, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Pulmonary Drug Delivery Systems Sales by Company
6.1.1.1 North America Pulmonary Drug Delivery Systems Sales by Company (2020-2025)
6.1.1.2 North America Pulmonary Drug Delivery Systems Revenue by Company (2020-2025)
6.1.2 North America Pulmonary Drug Delivery Systems Sales Breakdown by Type (2020-2025)
6.1.3 North America Pulmonary Drug Delivery Systems Sales Breakdown by Application (2020-2025)
6.1.4 North America Pulmonary Drug Delivery Systems Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Pulmonary Drug Delivery Systems Sales by Company
6.2.1.1 Europe Pulmonary Drug Delivery Systems Sales by Company (2020-2025)
6.2.1.2 Europe Pulmonary Drug Delivery Systems Revenue by Company (2020-2025)
6.2.2 Europe Pulmonary Drug Delivery Systems Sales Breakdown by Type (2020-2025)
6.2.3 Europe Pulmonary Drug Delivery Systems Sales Breakdown by Application (2020-2025)
6.2.4 Europe Pulmonary Drug Delivery Systems Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Pulmonary Drug Delivery Systems Sales by Company
6.3.1.1 China Pulmonary Drug Delivery Systems Sales by Company (2020-2025)
6.3.1.2 China Pulmonary Drug Delivery Systems Revenue by Company (2020-2025)
6.3.2 China Pulmonary Drug Delivery Systems Sales Breakdown by Type (2020-2025)
6.3.3 China Pulmonary Drug Delivery Systems Sales Breakdown by Application (2020-2025)
6.3.4 China Pulmonary Drug Delivery Systems Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Pulmonary Drug Delivery Systems Sales by Company
6.4.1.1 Japan Pulmonary Drug Delivery Systems Sales by Company (2020-2025)
6.4.1.2 Japan Pulmonary Drug Delivery Systems Revenue by Company (2020-2025)
6.4.2 Japan Pulmonary Drug Delivery Systems Sales Breakdown by Type (2020-2025)
6.4.3 Japan Pulmonary Drug Delivery Systems Sales Breakdown by Application (2020-2025)
6.4.4 Japan Pulmonary Drug Delivery Systems Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 India Market: Players, Segments, Downstream and Major Customers
6.5.1 India Pulmonary Drug Delivery Systems Sales by Company
6.5.1.1 India Pulmonary Drug Delivery Systems Sales by Company (2020-2025)
6.5.1.2 India Pulmonary Drug Delivery Systems Revenue by Company (2020-2025)
6.5.2 India Pulmonary Drug Delivery Systems Sales Breakdown by Type (2020-2025)
6.5.3 India Pulmonary Drug Delivery Systems Sales Breakdown by Application (2020-2025)
6.5.4 India Pulmonary Drug Delivery Systems Major Customer
6.5.5 India Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 3M
7.1.1 3M Company Information
7.1.2 3M Business Overview
7.1.3 3M Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.1.4 3M Pulmonary Drug Delivery Systems Products Offered
7.1.5 3M Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Business Overview
7.2.3 GSK Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.2.4 GSK Pulmonary Drug Delivery Systems Products Offered
7.2.5 GSK Recent Development
7.3 AstraZeneca
7.3.1 AstraZeneca Company Information
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.3.4 AstraZeneca Pulmonary Drug Delivery Systems Products Offered
7.3.5 AstraZeneca Recent Development
7.4 Cipla
7.4.1 Cipla Company Information
7.4.2 Cipla Business Overview
7.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Cipla Pulmonary Drug Delivery Systems Products Offered
7.4.5 Cipla Recent Development
7.5 Chiesi
7.5.1 Chiesi Company Information
7.5.2 Chiesi Business Overview
7.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Chiesi Pulmonary Drug Delivery Systems Products Offered
7.5.5 Chiesi Recent Development
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Information
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Boehringer Ingelheim Pulmonary Drug Delivery Systems Products Offered
7.6.5 Boehringer Ingelheim Recent Development
7.7 Aptar
7.7.1 Aptar Company Information
7.7.2 Aptar Business Overview
7.7.3 Aptar Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Aptar Pulmonary Drug Delivery Systems Products Offered
7.7.5 Aptar Recent Development
7.8 Novartis
7.8.1 Novartis Company Information
7.8.2 Novartis Business Overview
7.8.3 Novartis Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Novartis Pulmonary Drug Delivery Systems Products Offered
7.8.5 Novartis Recent Development
7.9 Philips Respironics
7.9.1 Philips Respironics Company Information
7.9.2 Philips Respironics Business Overview
7.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Philips Respironics Pulmonary Drug Delivery Systems Products Offered
7.9.5 Philips Respironics Recent Development
7.10 Omron Healthcare
7.10.1 Omron Healthcare Company Information
7.10.2 Omron Healthcare Business Overview
7.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Omron Healthcare Pulmonary Drug Delivery Systems Products Offered
7.10.5 Omron Healthcare Recent Development
7.11 PARI
7.11.1 PARI Company Information
7.11.2 PARI Business Overview
7.11.3 PARI Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.11.4 PARI Pulmonary Drug Delivery Systems Products Offered
7.11.5 PARI Recent Development
7.12 Skyepharma
7.12.1 Skyepharma Company Information
7.12.2 Skyepharma Business Overview
7.12.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.12.4 Skyepharma Pulmonary Drug Delivery Systems Products Offered
7.12.5 Skyepharma Recent Development
7.13 CareFusion
7.13.1 CareFusion Company Information
7.13.2 CareFusion Business Overview
7.13.3 CareFusion Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.13.4 CareFusion Pulmonary Drug Delivery Systems Products Offered
7.13.5 CareFusion Recent Development
7.14 Shanghai Huarui
7.14.1 Shanghai Huarui Company Information
7.14.2 Shanghai Huarui Business Overview
7.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.14.4 Shanghai Huarui Pulmonary Drug Delivery Systems Products Offered
7.14.5 Shanghai Huarui Recent Development
7.15 Taian Character
7.15.1 Taian Character Company Information
7.15.2 Taian Character Business Overview
7.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.15.4 Taian Character Pulmonary Drug Delivery Systems Products Offered
7.15.5 Taian Character Recent Development
7.16 Chia Tai Tianqing
7.16.1 Chia Tai Tianqing Company Information
7.16.2 Chia Tai Tianqing Business Overview
7.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2020-2025)
7.16.4 Chia Tai Tianqing Pulmonary Drug Delivery Systems Products Offered
7.16.5 Chia Tai Tianqing Recent Development
8 Pulmonary Drug Delivery Systems Manufacturing Cost Analysis
8.1 Pulmonary Drug Delivery Systems Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Pulmonary Drug Delivery Systems
8.4 Pulmonary Drug Delivery Systems Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Pulmonary Drug Delivery Systems Distributors List
9.3 Pulmonary Drug Delivery Systems Customers
10 Pulmonary Drug Delivery Systems Market Dynamics
10.1 Pulmonary Drug Delivery Systems Industry Trends
10.2 Pulmonary Drug Delivery Systems Market Drivers
10.3 Pulmonary Drug Delivery Systems Market Challenges
10.4 Pulmonary Drug Delivery Systems Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Ìý
Ìý
*If Applicable.
